MA42196A - Particules de fumarate de diméthyle et leurs compositions pharmaceutiques - Google Patents
Particules de fumarate de diméthyle et leurs compositions pharmaceutiquesInfo
- Publication number
- MA42196A MA42196A MA042196A MA42196A MA42196A MA 42196 A MA42196 A MA 42196A MA 042196 A MA042196 A MA 042196A MA 42196 A MA42196 A MA 42196A MA 42196 A MA42196 A MA 42196A
- Authority
- MA
- Morocco
- Prior art keywords
- pharmaceutical compositions
- dimethyl fumarate
- fumarate particles
- particles
- dimethyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562181061P | 2015-06-17 | 2015-06-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA42196A true MA42196A (fr) | 2018-04-25 |
Family
ID=56292916
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA042196A MA42196A (fr) | 2015-06-17 | 2016-06-15 | Particules de fumarate de diméthyle et leurs compositions pharmaceutiques |
Country Status (13)
Country | Link |
---|---|
US (2) | US11291642B2 (fr) |
EP (1) | EP3310341A1 (fr) |
JP (2) | JP2018517735A (fr) |
KR (1) | KR20180018711A (fr) |
CN (1) | CN107920997A (fr) |
AU (2) | AU2016279997B2 (fr) |
CA (1) | CA2989581A1 (fr) |
EA (1) | EA201890068A1 (fr) |
HK (1) | HK1254054A1 (fr) |
IL (1) | IL256296A (fr) |
MA (1) | MA42196A (fr) |
MX (1) | MX2017016509A (fr) |
WO (1) | WO2016205270A1 (fr) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2016344673A1 (en) * | 2015-10-28 | 2018-05-17 | Sun Pharmaceutical Industries Limited | Pharmaceutical compositions of dimethyl fumarate |
AU2017217464B2 (en) * | 2016-02-11 | 2022-11-10 | Biogen Ma Inc. | Pharmaceutical bead formulations comprising dimethyl fumarate |
EP3691616A1 (fr) * | 2017-10-02 | 2020-08-12 | Novartis AG | Procédé de préparation d'un produit pharmaceutique |
WO2019194826A1 (fr) | 2018-04-06 | 2019-10-10 | Hewlett-Packard Development Company, L.P. | Impression d'objet tridimensionnel (3d) basée sur la perméabilité d'un matériau de construction |
EP3860849A4 (fr) * | 2018-10-05 | 2022-06-22 | ISP Investments LLC | Composition de revêtement en film à haute teneur en solides lisse comprenant de l'éther de cellulose hydrosoluble, et procédé de préparation associé |
TR201818293A2 (tr) * | 2018-11-30 | 2020-06-22 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Di̇meti̇l fumarat i̇çeren geci̇kmeli̇ salim sağlayan kapsül |
AU2020214626A1 (en) * | 2019-01-31 | 2021-09-16 | Elektrofi, Inc. | Particle formation and morphology |
BR112021018496A2 (pt) * | 2019-03-20 | 2021-11-30 | Lyndra Therapeutics Inc | Cápsulas e revestimento de cápsula para formas de dosagem de residência gástrica |
AU2021391823A1 (en) | 2020-12-03 | 2023-06-29 | Battelle Memorial Institute | Polymer nanoparticle and dna nanostructure compositions and methods for non-viral delivery |
US12031128B2 (en) | 2021-04-07 | 2024-07-09 | Battelle Memorial Institute | Rapid design, build, test, and learn technologies for identifying and using non-viral carriers |
US11590071B2 (en) * | 2021-07-06 | 2023-02-28 | King Abdulaziz University | Injectable drug delivery implant composition and method of use thereof |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2725623A1 (fr) | 1994-10-18 | 1996-04-19 | Flamel Tech Sa | Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os |
US5972389A (en) | 1996-09-19 | 1999-10-26 | Depomed, Inc. | Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter |
DE19853487A1 (de) | 1998-11-19 | 2000-05-25 | Fumapharm Ag Muri | Verwendung von Dialkylfumaraten |
IL133196A0 (en) | 1999-11-29 | 2001-03-19 | Yissum Res Dev Co | Gastroretentive controlled release pharmaceutical dosage forms |
DE10101307A1 (de) * | 2001-01-12 | 2002-08-01 | Fumapharm Ag Muri | Fumarsäurederivate als NF-kappaB-Inhibitor |
US8101209B2 (en) | 2001-10-09 | 2012-01-24 | Flamel Technologies | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
US6723340B2 (en) | 2001-10-25 | 2004-04-20 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
PL1799196T3 (pl) * | 2004-10-08 | 2016-12-30 | Kompozycje farmaceutyczne o kontrolowanym uwalnianiu zawierające ester kwasu fumarowego | |
CA2637655C (fr) | 2006-01-18 | 2017-06-27 | Intec Pharma Ltd. | Procede et appareil permettant de former des dispositifs d'administration pour la prise orale d'un agent |
WO2009144558A1 (fr) * | 2008-04-18 | 2009-12-03 | Intec Pharma Ltd. | Apport de médicament à rétention gastrique à base de carbidopa/lipodopa |
UA103844C2 (ru) * | 2009-01-09 | 2013-11-25 | Форвард Фарма А/С | Фармацевтический состав, который содержит в матрице, которая подвергается эрозии, один или более эфиров фумаровой кислоты |
US20120034274A1 (en) * | 2009-01-09 | 2012-02-09 | Forward Pharma A/S | Pharmaceutical composition comprising one or more fumaric acid esters |
AU2012267524A1 (en) * | 2011-06-08 | 2013-12-12 | Biogen Ma Inc. | Process for preparing high purity and crystalline dimethyl fumarate |
RU2014125430A (ru) * | 2011-11-24 | 2015-12-27 | Синтон Бв | Контролируемое высвобождение частиц, содержащих диметилфумарат |
US20130216615A1 (en) * | 2012-02-07 | 2013-08-22 | David Goldman | Pharmaceutical Compositions Containing Dimethyl Fumarate |
WO2015042294A1 (fr) | 2013-09-18 | 2015-03-26 | Xenoport, Inc. | Compositions de nanoparticules de fumarate de diméthyle |
IN2013MU03070A (fr) | 2013-09-25 | 2015-07-17 | Glenmark Pharmaceuticals Ltd | |
WO2015089420A1 (fr) | 2013-12-13 | 2015-06-18 | Biogen Idec Ma Inc. | Forme pharmaceutique à libération contrôlée pour administration une fois par jour de fumarate de diméthyle |
ES2713157T3 (es) | 2014-02-28 | 2019-05-20 | Banner Life Sciences Llc | Cápsulas blandas entéricas de liberación controlada de ésteres de fumarato |
-
2016
- 2016-06-15 US US15/737,011 patent/US11291642B2/en active Active
- 2016-06-15 EP EP16733793.0A patent/EP3310341A1/fr not_active Withdrawn
- 2016-06-15 MX MX2017016509A patent/MX2017016509A/es unknown
- 2016-06-15 JP JP2017565133A patent/JP2018517735A/ja active Pending
- 2016-06-15 CN CN201680047251.2A patent/CN107920997A/zh active Pending
- 2016-06-15 KR KR1020187001091A patent/KR20180018711A/ko not_active Application Discontinuation
- 2016-06-15 AU AU2016279997A patent/AU2016279997B2/en not_active Ceased
- 2016-06-15 CA CA2989581A patent/CA2989581A1/fr active Pending
- 2016-06-15 MA MA042196A patent/MA42196A/fr unknown
- 2016-06-15 EA EA201890068A patent/EA201890068A1/ru unknown
- 2016-06-15 WO PCT/US2016/037486 patent/WO2016205270A1/fr active Application Filing
-
2017
- 2017-12-13 IL IL256296A patent/IL256296A/en unknown
-
2018
- 2018-10-12 HK HK18113117.1A patent/HK1254054A1/zh unknown
-
2021
- 2021-11-12 JP JP2021184469A patent/JP2022042512A/ja active Pending
-
2022
- 2022-01-12 AU AU2022200155A patent/AU2022200155A1/en not_active Abandoned
- 2022-02-22 US US17/677,204 patent/US20220362195A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2016205270A1 (fr) | 2016-12-22 |
KR20180018711A (ko) | 2018-02-21 |
AU2016279997B2 (en) | 2021-10-21 |
US20190070143A1 (en) | 2019-03-07 |
JP2018517735A (ja) | 2018-07-05 |
US11291642B2 (en) | 2022-04-05 |
AU2016279997A1 (en) | 2018-01-18 |
JP2022042512A (ja) | 2022-03-14 |
IL256296A (en) | 2018-02-28 |
EA201890068A1 (ru) | 2018-09-28 |
EP3310341A1 (fr) | 2018-04-25 |
CA2989581A1 (fr) | 2016-12-22 |
AU2022200155A1 (en) | 2022-02-10 |
US20220362195A1 (en) | 2022-11-17 |
WO2016205270A8 (fr) | 2017-01-19 |
HK1254054A1 (zh) | 2019-07-12 |
CN107920997A (zh) | 2018-04-17 |
MX2017016509A (es) | 2018-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA42196A (fr) | Particules de fumarate de diméthyle et leurs compositions pharmaceutiques | |
HK1259145A1 (zh) | 3-脫氧衍生物及其藥物組合物 | |
HK1251153A1 (zh) | 一種藥物組合物及其應用 | |
DK3529248T3 (da) | Farmaceutiske sammensætninger | |
MA50541A (fr) | Formulations pharmaceutiques | |
MA42303A (fr) | Formulations pharmaceutiques | |
EP3310376A4 (fr) | Agents thérapeutiques modifiés et compositions associées | |
EP3541385A4 (fr) | Formulations pharmaceutiques | |
IL265359B2 (en) | Modified oligonucleotides and pharmaceutical preparations containing them | |
MA49837A (fr) | Compositions pharmaceutiques | |
PL3145508T3 (pl) | Nanocząstki klewidypiny i ich kompozycje farmaceutyczne | |
EP3390348A4 (fr) | Dendrimère et formulations de ceux-ci | |
DK3313370T3 (da) | Oftalmologisk farmaceutisk sammensætning | |
HK1245113A1 (zh) | 藥物組合物及其用途 | |
DK3288933T3 (da) | Oxindolforbindelser og farmaceutiske sammensætninger deraf | |
PL3236938T3 (pl) | Doustne miejscowe wodne kompozycje farmaceutyczne flurbiprofenu i dekspantenolu | |
KR101809800B9 (ko) | 전복 내장 유래의 항알러지 효과를 가지는 펩타이드가 함유된 약학 조성물 | |
MA42552A (fr) | Compositions pharmaceutiques de flurbiprofène et de tramadol | |
EP3528818A4 (fr) | Compositions pharmaceutiques | |
IL254711B (en) | History of diazepine-indole and medicinal preparations containing them | |
MA43126A (fr) | Compositions pharmaceutiques de fumarate de diméthyle | |
MA49625A (fr) | Compositions pharmaceutiques | |
EP3651800C0 (fr) | Formulations pharmaceutiques hydrocompressées | |
DK3558261T3 (da) | Farmaceutiske sammensætninger omfattende safinamid | |
ZA201903341B (en) | Pharmaceutical compositions and uses thereof |